Sign in Join
  • Home
    • About Us
      • Privacy Policy
        • Disclaimer
    • Advertise On Market Exclusive
    • Sitemap
    • Submit a Scoop!
    • Contact Us
  • Stock Market News
  • Stocks
    • Analyst Ratings
    • Insider Trading
    • SEC Filings
    • Earnings
  • Cannabis Stocks News
  • Biotech Stocks
  • Small Caps
  • Blockchain & Cryptocurrency
  • Become a Contributor!
Sign in
Welcome!Log into your account
Forgot your password?
Sign up
Welcome!Register for an account
A password will be e-mailed to you.
Password recovery
Recover your password
Search
  • Sign in / Join
  • My Account
  • orders
Sign in
Welcome! Log into your account
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
A password will be e-mailed to you.
Password recovery
Recover your password
A password will be e-mailed to you.
Market Exclusive #1 Financial News & Analysis Market Exclusive
Market Exclusive #1 Financial News & Analysis
  • Home
    • About Us
      • Privacy Policy
        • Disclaimer
    • Advertise On Market Exclusive
    • Sitemap
    • Submit a Scoop!
    • Contact Us
  • Stock Market News
  • Stocks
    • Analyst Ratings
    • Insider Trading
    • SEC Filings
    • Earnings
  • Cannabis Stocks News
  • Biotech Stocks
  • Small Caps
  • Blockchain & Cryptocurrency
  • Become a Contributor!
Home SEC Filings CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
  • SEC Filings

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-
September 9, 2019
Share on Facebook
Tweet on Twitter

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
Item 7.01

On September 9, 2019, we are posting an investor presentation to our website (www.chembio.com). A copy of this investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated herein by reference.
The information contained herein, including the exhibit furnished hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.
CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1  Corporate PresentationSeptember 2019    © 2018 Chembio. All Rights Reserved. | #  © 2019 Chembio. All Rights Reserved. Page 1     Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,…
To view the full exhibit click here

Story continues below

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

An ad to help with our costs
SHARE
Facebook
Twitter
ME Staff 8-k

RELATED ARTICLESMORE FROM AUTHOR

Lumber Liquidators Holdings, Inc. (NYSE:LL) Files An 8-K Regulation FD Disclosure

EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Regulation FD Disclosure

SUPER MICRO COMPUTER, INC. (NASDAQ:SMCI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of...

CAN-CAL RESOURCES LTD. (OTCMKTS:CCRE) Files An 8-K Unregistered Sales of Equity Securities

SPAR Group, Inc. (NASDAQ:SGRP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain...

CESCA THERAPEUTICS INC. (NASDAQ:KOOL) Files An 8-K Entry into a Material Definitive Agreement

A word from the sponsor
Latest Articles
  • LIBERTY BROADBAND CORPORATION (NASDAQ:LBRDA) Files An 8-K Regulation FD Disclosure
  • REGENCY CENTERS CORPORATION (NYSE:REG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • ASSURED GUARANTY LTD. (NYSE:AGO) Files An 8-K Results of Operations and Financial Condition

Recent Posts

  • CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
  • Lumber Liquidators Holdings, Inc. (NYSE:LL) Files An 8-K Regulation FD Disclosure
  • EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Regulation FD Disclosure
  • Associated British Foods plc (LON:ABF) had its Buy rating reiterated by Liberum Capital
  • Abcam Plc (LON:ABC) had its Add rating reiterated by Peel Hunt with a GBX 1,300 price target
Sponsored
/* */

EDITOR PICKS

Cannabis Stock News Daily Roundup September 5

September 5, 2019
cannabis-news

Cannabis Stock News Daily Roundup September 4

September 4, 2019
Stock Market Roundup

Market Morning: Fed Debates, Johnson Loses, Hong Kong Wins, Italy Gets...

September 4, 2019

POPULAR POSTS

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016
biotechnology

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

POPULAR CATEGORY

  • SEC Filings88249
  • Analyst Ratings21563
  • Insider Trading7449
  • Earnings4727
  • LSE3996
  • dividend announcements2433
  • Tech News1583
  • Stocks1511
  • Stock Market News1474
Market Exclusive #1 Financial News & Analysis
ABOUT US
Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.
Contact us: [email protected]
FOLLOW US
  • SEC Filings
  • Stocks
  • Stock Market News
  • Tech News
  • Biotech Stocks
  • Featured
  • Small Caps
  • gold
  • Other News
  • Oil
  • Become a Contributor!
  • Advertise On Market Exclusive
  • Contact Us
© Market Exclusive 2019
// AST – IMS - [MarketExclusive_ROS]